Premium
Treatment of acute myelogenous leukemia: Influence of three induction regimens and maintenance with chemotherapy or BCG immunotherapy
Author(s) -
Omura George A.,
Vogler W. Ralph,
Lefante John,
Silberman Harold,
Knospe William,
Gordon David,
Jarrell Rhonda
Publication year - 1982
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19820415)49:8<1530::aid-cncr2820490804>3.0.co;2-1
Subject(s) - medicine , vincristine , maintenance therapy , chemotherapy , methotrexate , cytarabine , gastroenterology , leukemia , surgery , cyclophosphamide
The effect of a synchronizing‐recruiting drug schedule vs. myelotoxic therapy on remission rate and of Bacillus Calmette‐Guerin on remission duration and survival of adults with acute myelogenous leukemia were studied in a prospective cooperative trial. After randomized remission induction with Arabinosyl Cytosine + vincristine + methotrexate + leucovorin (AVML), thioguanine + Ara‐C + Daunorubin (TAD), or Daunorubicin + Ara‐C (DA), complete remissions (CR) were consolidated with TAD or AVML, CRs were maintained with BCG vaccination (Tice strain) by the tine technique, or BCNU plus Ara‐C (B/A), or no further therapy (NFT). Of 209 evaluable TAD patients, 105 (50%) achieved CR; of 187 DA, 97 (52%) achieved CR. AVML yielded only 15 CR among 59 patients (25%). The time to remission was significantly shorter with DA compared with TAD. Ninety‐seven patients were randomized to maintenance therapy (35 B/A, 30 BCG, 32 NFT). There were no differences in remission duration (7, 8, 6 months) or survival (16, 22, 16 months, respectively). Manipulation of the cell cycle, as employed in this study, was not helpful. There may be a marginal effect of BCG, but our data fail to show a statistically significant benefit.